Patient characteristics at time of HAART initiation by site.

NOTE. HAART, highly active antiretroviral therapy; FH-Argentina, Fundación Huésped in Buenos Aires; FA-Chile, Fundación Arriarán in Santiago, GHESKIO-Haiti, Le Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes in Port-au-Prince; IHSS/HE-Honduras Instituto Hondureño de Seguridad Social and Hospital de Especialidades in Tegucigalpa; INNSZ-Mexico, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City; and IMTAvH-Peru, Instituto de Medicina Tropical Alexander von Humboldt in Lima; LHI, late HAART initiators.aMedian (interquartile range) reported for all continuous variables except education years.bMissing values correspond to variables not routinely collected by some sites (e.g. marital status) or values not available within the required time frame (e.g. baseline CD4).cInformation about MSM transmission was only available in Argentina and Mexico. Argentina had 437 MSM (35.9%) and Mexico 312 MSM (65.1%).dMean (standard deviation) reported for education years.